Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

19.0%

11 terminated/withdrawn out of 58 trials

Success Rate

71.1%

-15.5% vs industry average

Late-Stage Pipeline

16%

9 trials in Phase 3/4

Results Transparency

81%

22 of 27 completed trials have results

Key Signals

3 recruiting22 with results8 terminated

Enrollment Performance

Analytics

Phase 1
24(42.9%)
Phase 2
23(41.1%)
Phase 3
8(14.3%)
Phase 4
1(1.8%)
56Total
Phase 1(24)
Phase 2(23)
Phase 3(8)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (58)

Showing 20 of 58 trials
NCT04774419Phase 2Recruiting

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

Role: collaborator

NCT03016338Phase 2Active Not Recruiting

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Role: collaborator

NCT03945721Phase 1Active Not Recruiting

A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients

Role: collaborator

NCT03651206Phase 2Recruiting

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

Role: collaborator

NCT04165772Phase 2Recruiting

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Role: collaborator

NCT03601923Phase 2Completed

Niraparib in Patients With Pancreatic Cancer

Role: collaborator

NCT02655016Phase 3Active Not Recruiting

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Role: lead

NCT03830918Phase 1Active Not Recruiting

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

Role: collaborator

NCT04068753Phase 2Active Not Recruiting

Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

Role: collaborator

NCT03368729Phase 1Active Not Recruiting

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Role: collaborator

NCT02715284Phase 1Active Not Recruiting

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Role: lead

NCT04221503Phase 2Active Not Recruiting

Niraparib/TTFields in GBM

Role: collaborator

NCT03955978Phase 1Active Not Recruiting

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Role: collaborator

NCT03602859Phase 3Active Not Recruiting

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Role: lead

NCT06964165Phase 2Terminated

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Role: lead

NCT03307785Phase 1Completed

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Role: lead

NCT02817633Phase 1Active Not Recruiting

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Role: lead

NCT04139902Phase 2Active Not Recruiting

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Role: collaborator

NCT03981796Phase 3Active Not Recruiting

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

Role: lead

NCT04080284Phase 2Completed

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Role: collaborator